Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health

Title: Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
Authors: Talbot, George H.; Powers, John H.; Hoffmann, Steven C.; for the Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams; Toerner, Joseph; Alder, Jeff; Ariyasu, Mari; Barriere, Steve; Boucher, Helen; Broom, Colin; Brunda, Michael; Cammarata, Sue; Cimms, Tricia; Coleman, Becky; Connolly, Lynn; Cox, Edward M.; Dane, Aaron; Das, Anita; Dixon, Dennis; Dudley, Mike; Eisenstein, Barry; Echols, Roger; El-Akkad, Tarek; File, Thomas; Fleming, Thomas R.; Follmann, Dean; Friedland, H. David; Friedland, Ian; Kartsonis, Nicholas A.; Kaufhold, Achim; Kindrick, Amy; Lesnick, Marc; Llorens, Lily; Loutit, Jeff; Powers, John; Prokocimer, Philippe; Rex, John H.; Rubin, Dan; Slagle, Ashley; Suffredini, Anthony; Torres, Antoni; Tsai, Larry; Wible, Michele; Wunderink, Richard
Publisher Information: Oxford University Press
Publication Year: 2016
Collection: HighWire Press (Stanford University)
Subject Terms: VIEWPOINTS
Description: One important component in determining the benefits and harms of medical interventions is the use of well-defined and reliable outcome assessments as endpoints in clinical trials. Improving endpoints can better define patient benefits, allowing more accurate assessment of drug efficacy and more informed benefit-vs-risk decisions; another potential plus is facilitating efficient trial design. Since our first report in 2012, 2 Foundation for the National Institutes of Health Biomarkers Consortium Project Teams have continued to develop outcome assessments for potential uses as endpoints in registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. In addition, the teams have initiated similar work in the indications of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This report provides an update on progress to date in these 4 diseases.
Document Type: text
File Description: text/html
Language: English
Relation: http://cid.oxfordjournals.org/cgi/content/short/62/5/603; http://dx.doi.org/10.1093/cid/civ927
DOI: 10.1093/cid/civ927
Availability: http://cid.oxfordjournals.org/cgi/content/short/62/5/603; https://doi.org/10.1093/cid/civ927
Rights: Copyright (C) 2016, Infectious Diseases Society of America
Accession Number: edsbas.F9345855
Database: BASE